Bloom Science

Executive Summary

Bloom Science is a private microbiome company developing BL-001, a live biotherapeutic product engineered to replicate the clinical efficacy of the ketogenic diet. The company has demonstrated proof of mechanism and an encouraging safety profile in preclinical studies, and is now planning Phase 2 clinical trials in two major indications: obesity and Dravet syndrome. This dual-track approach leverages a single platform to address both metabolic and neurological disorders, potentially offering a novel, non-systemic therapy. Bloom Science is based in San Diego, California, and operates at the intersection of the microbiome and drug development. The company’s strategy is to provide a well-tolerated alternative to the restrictive ketogenic diet, which has established clinical benefits but poor patient compliance. With a clear path to Phase 2 and a strong scientific rationale, Bloom Science represents an early-stage opportunity in the emerging live biotherapeutic space, though it remains pre-revenue and has not disclosed funding details.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 2 clinical trial in obesity60% success
• Q4 2026Initiation of Phase 2 clinical trial in Dravet syndrome55% success
• Q3 2026Announcement of Series A financing or strategic partnership50% success